Síguenos en Twitter     Síguenos en Facebook     Síguenos en Google+     Síguenos en YouTube     Siguenos en Linkedin     Correo Grupsagessa     Gmail     Yahoo Mail     Dropbox     Instagram     Pinterest     Slack     Google Drive     Reddit     StumbleUpon     Print

SOBRE EL AUTOR **

Mi foto
FACP. Colegio de médicos de Tarragona Nº 4305520 / fgcapriles@gmail.com

WORLD EMERGENCY MEDICINE SOCIETIES

Cranial Nerve VI Palsy Emergency

Buscar en contenido

Contenido:

lunes, 7 de diciembre de 2015

EE-3-SO4 (Ethynylestradiol-3-sulfate)

UAB News - By Bob Shepard - October 21, 2015
"The University of Alabama at Birmingham will launch the first Phase 1 human trials of a drug — derived from the female hormone estrogen — that may help patients with severe bleeding survive long enough to get to appropriate medical care. A three year, $10 million U.S. Department of Defense contract from the Combat Casualty Care Research Program, U.S. Army Medical Research and Materiel Command, Fort Detrick MD, will fund studies of a synthetic estrogen molecule that may have a profound effect on an individual’s ability to survive major blood loss.
The initial observations and subsequent research in animal models was done by Irshad H. Chaudry, Ph.D., professor in the Department of Surgery at UAB and co-principal investigator on the contract. Chaudry and his colleagues discovered that following severe bleeding, a single injection increased survival times even in the absence of any fluid resuscitation. Time is the key. Severely hemorrhaging patients — those who experience approximately 40 percent or more blood loss — who do not receive fluid or blood product resuscitation within a few hours usually do not survive.
“The work of Dr. Chaudry and colleagues showed that EE-3-SO4 is extremely effective in improving cardiovascular functions and boosting survival rates following injuries with extreme hemorrhage,” said principal investigator Mansoor Saleh, M.D., professor in the Division of Hematology/Oncology, Department of Medicine, and director of the UAB Phase 1 Clinical Trials Program. “This drug could have major implications for treating trauma, from battlefield injuries to life threatening hemorrhage following any injury. We are excited to be launching the first-in-human studies of this drug that was developed by one of our own here at UAB. This is a classic example of bench-to-bedside translational research.”
http://www.uab.edu/news/innovation/item/6624-uab-to-start-first-human-trials-of-drug-to-prevent-death-due-to-severe-blood-loss